Checkpoint inhibitors work by releasing the brakes on your immune system so it can hunt down cancer cells — but that unleashed immune system does not always distinguish friend from foe. Between 56 and 96 percent of patients treated with these drugs experience some form of autoimmune side effect, where the body’s own defenses turn against healthy organs like the skin, gut, liver, heart, and even the brain. For families already navigating cognitive decline or dementia, understanding these risks matters enormously, because neurological side effects — though less common — can mimic or worsen symptoms that look like dementia, and the corticosteroids used to treat immune reactions carry their own cognitive costs. Consider a 72-year-old woman being treated with pembrolizumab for lung cancer who begins showing confusion, memory lapses, and difficulty finding words six weeks into therapy. Her family assumes the cancer is progressing or her existing mild cognitive impairment is worsening.
In fact, she is experiencing immune-mediated encephalitis — her own T cells attacking her brain tissue. This scenario, while affecting only one to five percent of patients on checkpoint inhibitors, illustrates why caregivers and families dealing with brain health concerns need to understand what these drugs can do. This article covers how checkpoint inhibitors trigger autoimmune attacks across every major organ system, which side effects are most dangerous, who faces the highest risk, and what treatment options exist when the immune system turns on itself. As of 2024, eleven checkpoint inhibitors are FDA-approved across 43 distinct indications, with pembrolizumab (Keytruda) alone covering 35 of those. The global market reached approximately $52 to $66 billion in 2025 and is projected to climb to $60 to $76 billion in 2026. These numbers matter because they signal how many patients are now exposed to these drugs — and how urgently we need to understand the collateral damage they can cause.
Table of Contents
- What Exactly Happens When Checkpoint Inhibitors Cause Your Immune System to Attack Itself?
- Which Organs Are Most Vulnerable to Immune Attack — and Which Reactions Are Deadliest?
- When Do Side Effects Appear — and Can They Strike After Treatment Ends?
- Who Is Most at Risk — and How Should That Shape Treatment Decisions?
- How Are Immune-Related Side Effects Treated — and What Happens When Steroids Fail?
- New Checkpoint Inhibitor Approvals in 2025 Mean More Patients Are Exposed
- Where Research Is Headed — Predicting and Preventing Immune Attacks Before They Start
- Conclusion
- Frequently Asked Questions
What Exactly Happens When Checkpoint Inhibitors Cause Your Immune System to Attack Itself?
Your immune system has a built-in safety mechanism. Proteins called PD-1, PD-L1, and CTLA-4 act as checkpoints — molecular handshakes between immune cells and healthy tissue that say “don’t attack me.” Cancer cells exploit these checkpoints by displaying the same proteins, essentially disguising themselves as normal cells. Checkpoint inhibitors block these proteins, stripping away the disguise so T cells can recognize and destroy tumors. The problem is that these checkpoints were not designed solely to protect cancer cells. They protect every organ in your body. Remove the brakes system-wide, and the immune system can attack the thyroid, the colon, the liver, the heart, the lungs, or the nervous system with the same ferocity it directs at a tumor. The medical term for these collateral attacks is immune-related adverse events, or irAEs. A 2025 systematic review published in the British Journal of Cancer found that the mean irAE rate across any grade was 40.0 percent, with high-grade (severe or life-threatening) events occurring in 19.7 percent of patients.
A separate 2025 real-world cohort study tracking 6,526 patients found that 56.2 percent developed irAEs within one year, resulting in 284 hospitalizations. Compare this to traditional chemotherapy, where side effects are caused by the drug itself poisoning fast-dividing cells. With checkpoint inhibitors, the drug is not directly causing the damage — your own immune system is. That distinction changes everything about how these side effects behave, how long they last, and how they must be treated. The comparison between different checkpoint inhibitor classes is instructive. CTLA-4 inhibitors like ipilimumab tend to cause more frequent and more severe side effects than PD-1 or PD-L1 inhibitors like nivolumab or pembrolizumab. When oncologists combine both classes — a strategy that can be more effective against certain cancers — the risk of irAEs jumps by 35 percent compared to PD-1 monotherapy. This is the fundamental tradeoff that patients, families, and care teams must weigh: more immune activation means more cancer-fighting power, but also more friendly fire.
Which Organs Are Most Vulnerable to Immune Attack — and Which Reactions Are Deadliest?
The skin is the most frequently targeted organ, affected in 46 to 62 percent of patients. Maculopapular rash appears in up to 60 percent of those on CTLA-4 inhibitors and about 24 percent of those on PD-1 inhibitors. While skin reactions are common, they are rarely fatal. The gastrointestinal tract is next, with colitis affecting 22 to 48 percent of patients. This is where the danger escalates sharply: fatal colitis and enteritis account for 70 percent of all deaths attributed to anti-CTLA-4 therapy. Liver inflammation, or hepatitis, appears in 7 to 33 percent of patients, typically emerging between 6 and 14 weeks after starting treatment. Endocrine disruption — thyroid dysfunction, inflammation of the pituitary gland, and even new-onset type 1 diabetes — occurs in 12 to 34 percent of patients, with thyroid problems showing up at a median of about 42 days. Notably, checkpoint inhibitor-associated diabetes appears almost exclusively with anti-PD-1 and anti-PD-L1 drugs. However, the deadliest complication is not the most common one.
Myocarditis — inflammation of the heart muscle — occurs in roughly five percent of patients but carries a mortality rate of 27 to 60 percent, the highest of any immune-related adverse event. Patients receiving combination ipilimumab-nivolumab face a staggering 60 percent myocarditis fatality rate. Pneumonitis, affecting 3 to 8 percent of patients with a median onset of 2.6 months, is responsible for 35 percent of deaths from anti-PD-1 and anti-PD-L1 therapy. Kidney inflammation occurs in 1 to 7 percent of patients, typically at around 14 weeks. For readers of a brain health site, the neurological effects demand particular attention. Neurological irAEs affect 1 to 5 percent of patients, but the range of presentations is wide: encephalitis, meningitis, peripheral neuropathy, myasthenia gravis, and Guillain-Barré syndrome have all been documented. A retrospective study of 3,545 patients found that cardiac and neurological events together accounted for 43 percent of treatment-related deaths, despite being among the rarer side effects. If someone you care for is already living with cognitive impairment or early-stage dementia, a neurological irAE can be misattributed to disease progression rather than a treatable drug reaction — a misdiagnosis with serious consequences. The overall fatal toxicity rate across all checkpoint inhibitors falls between 0.3 and 1.3 percent, with one study finding 0.6 percent mortality.
When Do Side Effects Appear — and Can They Strike After Treatment Ends?
Timing is one of the most unsettling aspects of checkpoint inhibitor toxicity. Most irAEs appear within three months of starting treatment, but the window is far wider than many patients and families expect. Skin reactions can erupt within 24 hours of the first infusion. Endocrine side effects tend to emerge around six weeks in. Hepatitis surfaces between 6 and 14 weeks. Pneumonitis has a median onset of 2.6 months but can appear anywhere from two weeks to 11.5 months into therapy. Myocarditis typically strikes within 4 to 6 weeks — early enough that families are still adjusting to the treatment routine when a cardiac emergency arrives. What makes checkpoint inhibitors fundamentally different from conventional chemotherapy in this regard is that side effects can appear months or even years after a patient has stopped treatment.
According to MD Anderson Cancer Center, late-onset irAEs are a recognized phenomenon. This happens because checkpoint inhibitors do not leave the body the way a traditional drug does. They reprogram the immune system’s behavior, and that reprogramming can persist long after the antibodies themselves have been cleared. For caregivers managing a loved one’s overall health, this means that a new symptom appearing six months after the last infusion should not be automatically dismissed as unrelated to immunotherapy. Thyroid dysfunction, in particular, is frequently permanent — the immune system can destroy enough thyroid tissue during treatment that the gland never recovers, requiring lifelong hormone replacement. This delayed-onset profile creates a practical challenge for dementia caregivers. A person with Alzheimer’s disease who received checkpoint inhibitor therapy for a concurrent cancer diagnosis might develop new confusion, tremor, or personality changes a year later. Without a high index of suspicion, these symptoms get filed under “disease progression” rather than triggering the workup for a late neurological irAE. The lesson is straightforward: keep immunotherapy on the problem list indefinitely, not just during active treatment.
Who Is Most at Risk — and How Should That Shape Treatment Decisions?
Not every patient faces equal odds of immune-related side effects. Research published in the World Journal of Oncology has identified several demographic and clinical risk factors. Younger adults between 18 and 29 face higher irAE rates than older patients — counterintuitive, since younger immune systems are generally considered an advantage. Female sex independently increases risk. Pre-existing conditions including heart failure and renal disease compound vulnerability. Perhaps most significant for treatment planning, patients with pre-existing autoimmune diseases face substantially elevated risk. A study in JAMA Oncology found that people with psoriasis or psoriatic arthritis carry the highest irAE risk among autoimmune disease patients, while those with rheumatoid arthritis experience disease flares approximately 60 percent of the time during checkpoint inhibitor therapy.
On the biomarker front, researchers at Stanford and the University of Washington identified high levels of CD4 effector memory T cells in the blood as a predictor of severe irAE development. This finding, published in Frontiers in Immunology, offers hope for eventually screening patients before treatment begins — identifying who is likely to experience dangerous autoimmune reactions and adjusting the treatment plan accordingly. However, this biomarker is not yet part of standard clinical practice, so at present, risk stratification relies primarily on clinical history and vigilant monitoring. The tradeoff that oncologists and patients must navigate is stark. Combination therapy — using both a CTLA-4 and a PD-1 inhibitor — is the most effective regimen for several cancer types, including advanced melanoma. But combination therapy also carries that 35 percent higher risk of irAEs. For a patient with a pre-existing autoimmune condition, starting on monotherapy and escalating only if needed may be the safer path, even if it means sacrificing some efficacy. For patients with dementia or significant cognitive impairment, the calculation includes another variable: can this patient reliably report early symptoms like subtle changes in vision, tingling, or chest pressure? If not, the monitoring burden falls entirely on caregivers and clinicians, and the threshold for choosing a less aggressive regimen may reasonably be lower.
How Are Immune-Related Side Effects Treated — and What Happens When Steroids Fail?
The standard first-line treatment for most irAEs is corticosteroids, following guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). For grade 2 events — moderate symptoms that interfere with daily activities — the typical approach is prednisone at 1 to 2 milligrams per kilogram per day. Grade 3 and 4 events — severe or life-threatening — call for intravenous methylprednisolone. The goal is to suppress the runaway immune response quickly enough to prevent permanent organ damage. But steroids are not a universal solution, and this is a critical limitation that patients and families should understand. Up to 40 percent of pneumonitis cases prove steroid-refractory, meaning the lung inflammation does not respond adequately to corticosteroids. In these cases, second-line agents include mycophenolate mofetil (MMF) and intravenous immunoglobulin (IVIG).
Infliximab, once commonly used, has fallen out of favor for pneumonitis due to concerns about increasing infection risk in already immunocompromised patients. For severe myocarditis — the irAE with the highest mortality — treatment escalation must happen rapidly, and even aggressive immunosuppression does not always prevent fatal outcomes. There is an additional concern that is particularly relevant for brain health. High-dose corticosteroids are themselves associated with cognitive side effects: confusion, agitation, psychosis, insomnia, and memory disturbance. For a patient already dealing with mild cognitive impairment or early dementia, a course of high-dose prednisone or methylprednisolone can produce dramatic behavioral changes that are difficult to distinguish from a neurological irAE or from dementia progression. This creates a diagnostic tangle where the treatment for one problem mimics another. In severe cases, the immunotherapy must be permanently discontinued — a decision that trades cancer-fighting capacity for the patient’s immediate survival and quality of life. The American Cancer Society notes that permanent discontinuation is sometimes the only safe path forward.
New Checkpoint Inhibitor Approvals in 2025 Mean More Patients Are Exposed
The pipeline of checkpoint inhibitor approvals shows no sign of slowing. In 2025, the FDA issued over 50 oncology approvals, with 20 in the fourth quarter alone. Among the notable new indications: cemiplimab (Libtayo) became the first adjuvant immunotherapy approved for high-risk cutaneous squamous cell carcinoma after surgery, pembrolizumab (Keytruda) gained approval alongside enfortumab vedotin for muscle-invasive bladder cancer in patients who cannot tolerate cisplatin, and durvalumab (Imfinzi) became the first immunotherapy approved for early-stage stomach and gastroesophageal cancer in both the neoadjuvant and adjuvant settings.
Each new approval expands the population of patients who will be exposed to immune-related side effects. Many of these newer indications involve earlier-stage cancers, meaning patients who are otherwise healthier and may live longer with their side effects — including any that are permanent, like thyroid destruction or chronic colitis. For the dementia care community, the expanding use of checkpoint inhibitors in older adults with solid tumors increases the likelihood that someone under your care will encounter these drugs and their consequences.
Where Research Is Headed — Predicting and Preventing Immune Attacks Before They Start
The most promising frontier in checkpoint inhibitor safety is not better treatment of side effects but prediction and prevention. The CD4 effector memory T cell biomarker identified by Stanford and University of Washington researchers represents a step toward blood tests that could flag high-risk patients before they receive their first infusion. If validated in larger trials, such a test could allow oncologists to choose between combination and monotherapy based on individualized immune profiling rather than population-level statistics.
Other research directions include investigating whether lower or intermittent dosing schedules can maintain cancer efficacy while reducing autoimmune toxicity, developing targeted immunosuppressants that can quell an irAE without broadly suppressing the anti-tumor immune response, and building better surveillance systems for late-onset events that currently slip through follow-up gaps. For patients with concurrent neurological conditions, the development of checkpoint inhibitors with reduced blood-brain barrier penetration could eventually separate the anti-cancer benefit from the neurological risk. None of these advances are available today, but they define where the field is heading — and they underscore why long-term monitoring of every patient who has ever received a checkpoint inhibitor remains essential.
Conclusion
Checkpoint inhibitors have transformed cancer treatment, but their mechanism of action — removing the immune system’s natural restraints — guarantees a significant burden of autoimmune side effects. With 56 to 96 percent of patients experiencing some form of immune-related adverse event, and side effects ranging from manageable skin rashes to fatal myocarditis with mortality rates as high as 60 percent, these are not drugs whose risks can be treated as afterthoughts. The timing is unpredictable, with reactions appearing anywhere from 24 hours to years after treatment, and certain populations — younger patients, women, those with pre-existing autoimmune conditions — face elevated vulnerability. For families and caregivers in the dementia and brain health space, the takeaway is specific and actionable.
If someone in your care is receiving or has ever received a checkpoint inhibitor, maintain a high index of suspicion for new neurological, cognitive, or behavioral symptoms regardless of how long ago treatment ended. Communicate the full medication history to every clinician involved in care. Understand that the steroids used to treat side effects can themselves cause cognitive disruption. And recognize that the decision to start, continue, or stop checkpoint inhibitor therapy involves tradeoffs that should account for the patient’s overall cognitive and functional status — not just the cancer. These are conversations worth having early, with the full care team at the table.
Frequently Asked Questions
Can checkpoint inhibitor side effects be mistaken for dementia symptoms?
Yes. Neurological immune-related adverse events can cause confusion, memory problems, personality changes, and difficulty with language — symptoms that overlap significantly with Alzheimer’s disease and other dementias. If new cognitive symptoms appear in someone receiving or who has received checkpoint inhibitors, an irAE workup should be considered alongside other explanations.
How long after stopping checkpoint inhibitor therapy can side effects still appear?
Late-onset irAEs can emerge months or even years after the last dose. This is because checkpoint inhibitors reprogram immune system behavior rather than acting as conventional drugs that are metabolized and cleared. Thyroid dysfunction and other endocrine effects are particularly likely to be permanent.
Are older adults at higher risk for checkpoint inhibitor side effects?
Counterintuitively, younger adults (18 to 29) appear to face higher irAE rates. However, older adults are more likely to have comorbidities like heart failure and renal disease that increase risk, and they may be less able to tolerate the high-dose steroids used for treatment. Older adults with cognitive impairment may also have more difficulty recognizing and reporting early symptoms.
What is the most dangerous side effect of checkpoint inhibitors?
Myocarditis, or inflammation of the heart muscle, carries the highest mortality rate of any irAE at 27 to 60 percent. Patients on combination ipilimumab-nivolumab therapy face a 60 percent fatality rate from myocarditis. Cardiac and neurological events together account for 43 percent of all checkpoint inhibitor treatment-related deaths.
Can someone with a pre-existing autoimmune disease receive checkpoint inhibitors?
It is possible but carries elevated risk. Patients with rheumatoid arthritis experience disease flares about 60 percent of the time during treatment, and those with psoriasis or psoriatic arthritis face the highest overall irAE risk. Oncologists may opt for monotherapy rather than combination therapy and implement closer monitoring in these patients.
If side effects appear, does treatment always have to stop?
Not always. Mild to moderate irAEs (grade 1 to 2) can often be managed with corticosteroids while continuing or temporarily pausing immunotherapy. However, severe events (grade 3 to 4), steroid-refractory cases, and life-threatening reactions like myocarditis typically require permanent discontinuation.
